Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Chronic Spontaneous Urticaria Symptomatic Despite Antihistamines (Phase 2b)
2020-000169-17Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) and urticaria comparing Benralizumab with Placebo (2 arms). Primary endpoint: Change from baseline in ISS7 at Week 12. Started Sep 2020; status: terminated.
02
Drugs
benralizumab
03
Conditions
chronic idiopathic urticaria (CIU)urticaria
Beyond the preview
Go deeper on 2020-000169-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000169-17.